Compare III & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | III | NYXH |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | Belgium |
| Employees | 1500 | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.8M | 152.8M |
| IPO Year | 2006 | 2021 |
| Metric | III | NYXH |
|---|---|---|
| Price | $4.34 | $3.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.50 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 201.1K | 48.4K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | ★ 216.67 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $192,745,000.00 | N/A |
| Revenue This Year | $3.85 | $214.32 |
| Revenue Next Year | $4.34 | $124.13 |
| P/E Ratio | $22.84 | ★ N/A |
| Revenue Growth | ★ 4.51 | N/A |
| 52 Week Low | $3.57 | $2.76 |
| 52 Week High | $6.45 | $8.64 |
| Indicator | III | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 60.10 | 49.73 |
| Support Level | $4.12 | $2.78 |
| Resistance Level | $5.14 | $3.32 |
| Average True Range (ATR) | 0.12 | 0.19 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 92.87 | 58.82 |
Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.